<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:g-custom="http://base.google.com/cns/1.0" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
  <channel>
    <title>nu-flo</title>
    <link>https://www.nuflomenshealth.com</link>
    <description />
    <atom:link href="https://www.nuflomenshealth.com/feed/rss2" type="application/rss+xml" rel="self" />
    <item>
      <title>A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial</title>
      <link>https://www.nuflomenshealth.com/article5</link>
      <description />
      <content:encoded>&lt;div data-rss-type="text"&gt;&#xD;
  
         One hundred patients with a history of PD not 
         &#xD;
  &lt;span&gt;&#xD;
    
          &amp;gt;12 mo who had not had previous PD-related treatments were enrolled in a 
         &#xD;
  &lt;/span&gt;&#xD;
  &lt;span&gt;&#xD;
    
          prospective, randomized, double-blind, placebo-controlled study. Patients were 
         &#xD;
  &lt;/span&gt;&#xD;
  &lt;span&gt;&#xD;
    
          randomly allocated to either ESWT (n = 50) or placebo (n = 50). Erectile function 
         &#xD;
  &lt;/span&gt;&#xD;
  &lt;span&gt;&#xD;
    
          (EF), pain during erection, plaque size, penile curvature, and quality of life (QoL) 
         &#xD;
  &lt;/span&gt;&#xD;
  &lt;span&gt;&#xD;
    
          were assessed at baseline, at 12 wk, and at 24 wk follow-up
         &#xD;
  &lt;/span&gt;&#xD;
&lt;/div&gt;</content:encoded>
      <enclosure url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg" length="73728" type="image/jpeg" />
      <pubDate>Wed, 15 Sep 2021 20:46:09 GMT</pubDate>
      <guid>https://www.nuflomenshealth.com/article5</guid>
      <g-custom:tags type="string" />
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>thumbnail</media:description>
      </media:content>
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>main image</media:description>
      </media:content>
    </item>
    <item>
      <title>A study In An Indian Population</title>
      <link>https://www.nuflomenshealth.com/article6</link>
      <description />
      <content:encoded>&lt;div data-rss-type="text"&gt;&#xD;
  
         In this double-blind, placebo-controlled study, LI-ESWT demonstrated a positive long term clinical effect with improvement in erectile function of Indian men with vasculogenic ED who were prior responders to PDE5i therapy.
        &#xD;
&lt;/div&gt;</content:encoded>
      <enclosure url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg" length="73728" type="image/jpeg" />
      <pubDate>Wed, 15 Sep 2021 20:46:08 GMT</pubDate>
      <guid>https://www.nuflomenshealth.com/article6</guid>
      <g-custom:tags type="string" />
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>thumbnail</media:description>
      </media:content>
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>main image</media:description>
      </media:content>
    </item>
    <item>
      <title>Can low-intensity extracorporeal shockwave therapy improve erectile function?</title>
      <link>https://www.nuflomenshealth.com/arcticle1</link>
      <description />
      <content:encoded>&lt;div data-rss-type="text"&gt;&#xD;
  &lt;p&gt;&#xD;
    &lt;span&gt;&#xD;
      
           This is the first study that assessed the efficacy of LI-ESWT for ED. This approach was tolerable and effective, suggesting a physiologic impact on cavernosal hemodynamics. Its main advantages are the potential to improve erectile function and to contribute to penile rehabilitation without pharmacotherapy. The short-term results are promising, yet demand further evaluation with larger sham-control cohorts and longer follow-up.
          &#xD;
    &lt;/span&gt;&#xD;
  &lt;/p&gt;&#xD;
&lt;/div&gt;</content:encoded>
      <enclosure url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg" length="73728" type="image/jpeg" />
      <pubDate>Mon, 01 Jul 2019 11:38:31 GMT</pubDate>
      <guid>https://www.nuflomenshealth.com/arcticle1</guid>
      <g-custom:tags type="string" />
      <media:content medium="image" url="https://irp-cdn.multiscreensite.com/md/dmtmpl/72636a6b-a692-4171-801b-0c27f91c8c21/dms3rep/multi/blank_image_2.jpg">
        <media:description>thumbnail</media:description>
      </media:content>
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>main image</media:description>
      </media:content>
    </item>
    <item>
      <title>Shockwave treatment of erectile dysfunction</title>
      <link>https://www.nuflomenshealth.com/article2</link>
      <description />
      <content:encoded>&lt;div data-rss-type="text"&gt;&#xD;
  &lt;p&gt;&#xD;
    &lt;span&gt;&#xD;
      
           Low-intensity extracorporeal shock wave therapy (LI-ESWT) is a novel modality that has recently been developed for treating erectile dysfunction (ED). Unlike other current treatment options for ED, all of which are palliative in nature, LI-ESWT is unique in that it aims to restore the erectile mechanism in order to enable natural or spontaneous erections.
          &#xD;
    &lt;/span&gt;&#xD;
  &lt;/p&gt;&#xD;
&lt;/div&gt;</content:encoded>
      <enclosure url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg" length="73728" type="image/jpeg" />
      <pubDate>Mon, 01 Jul 2019 11:37:25 GMT</pubDate>
      <guid>https://www.nuflomenshealth.com/article2</guid>
      <g-custom:tags type="string" />
      <media:content medium="image" url="https://irp-cdn.multiscreensite.com/md/dmtmpl/72636a6b-a692-4171-801b-0c27f91c8c21/dms3rep/multi/blank_image_2.jpg">
        <media:description>thumbnail</media:description>
      </media:content>
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>main image</media:description>
      </media:content>
    </item>
    <item>
      <title>Extracorporeal shockwave therapy in the treatment of erectile dysfunction</title>
      <link>https://www.nuflomenshealth.com/article3</link>
      <description />
      <content:encoded>&lt;div data-rss-type="text"&gt;&#xD;
  &lt;p&gt;&#xD;
    &lt;span&gt;&#xD;
      
           This was a double-blinded, single-center, prospective, randomized, placebo-controlled trial. After a 2-week phosphodiesterase type 5 inhibitor washout period, patients were assessed with Sexual Health Inventory for Men, International Index of Erectile Function-ED domain scores and Erection Hardness Score.
          &#xD;
    &lt;/span&gt;&#xD;
  &lt;/p&gt;&#xD;
&lt;/div&gt;</content:encoded>
      <enclosure url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg" length="73728" type="image/jpeg" />
      <pubDate>Mon, 15 Apr 2019 12:41:17 GMT</pubDate>
      <guid>https://www.nuflomenshealth.com/article3</guid>
      <g-custom:tags type="string" />
      <media:content medium="image" url="https://irp-cdn.multiscreensite.com/md/dmtmpl/72636a6b-a692-4171-801b-0c27f91c8c21/dms3rep/multi/blank_image_2.jpg">
        <media:description>thumbnail</media:description>
      </media:content>
      <media:content medium="image" url="https://irp.cdn-website.com/b5d573c3/dms3rep/multi/AdobeStock_358374087--Converted-.jpg">
        <media:description>main image</media:description>
      </media:content>
    </item>
  </channel>
</rss>
